Ligand (LGND) Pharmaceuticals announced the completion of its previously announced merger between the company’s wholly owned subsidiary, LNHC and CHRO Merger Sub, a wholly owned subsidiary of Channel Therapeutics Corporation. The combined company will operate under the name Pelthos Therapeutics and will commence trading on the NYSE American exchange under the new ticker symbol “PTHS” on July 2, 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGND:
- Ligand Pharma Elects Board Members at Annual Meeting
- Ligand price target raised to $145 from $142 at Oppenheimer
- Ligand Pharma’s Strong Q1 Performance and Strategic Moves Justify Buy Rating with $135 Price Target
- Ligand Pharmaceuticals Reports Strong Q1 2025 Revenue Growth
- Ligand Pharmaceuticals Reports Strong Q1 2025 Earnings